News
Kisqali® Receives Positive Draft Recommendation From Canada's Drug Agency For All Eligible Early Breast Cancer Patients at High Risk of Recurrence
8+ hour, 17+ min ago (926+ words) The draft recommendation for Kisqali" (ribociclib tablets) from Canada's Drug Agency (CDA-AMC) supports public reimbursement for hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative stage II-III early breast cancer (eBC) in patients at high risk of recurrence.1 Breast…...